Skip to main content
OpenTrials
Completed

NCT Number: NCT05195502

Mapping the Human Colon Using Single Cell Sequencing

The overall purpose of this study is to describe the cellular composition of the human colon and its gene expression using scRNAseq and scATACseq methods. This will potentially provide is with a detailed map of the colon aiding our understanding of how diseases of the colon develop as well as the colons influence on systemic diseases such as type II diabetes.

Completed

Looking for future studies?

Notify Me

Key information

About this study

The human colon is composed of four distinct histological layers: Serosa, muscularis externa, submucosa, and mucosa. The inner mucosal surface is composed of columnar epithelium and glandular tissue containing crypts of Lieberkühn and secretory goblet cells, lamina propria and muscularis mucosa. Several distinct cell types have been discovered in varying degree in the colon for example enteroendocrine cells and M-cells.

The cellular composition, patterns of gene expression and upstream regulatory pathways of the human colon varies across different anatomical location. This is evident in the anatomical bias in benign and malignant colorectal diseases. For example, the distal colon has a higher incidens of ulcerative colitis, diverticulitis, and chromosomal instability cancer whereas in the proximal colon ischemic colitis, collagenous colitis and microsatellite instability-induced cancer are predominant.

Currently there are no studies describing baseline data for genome-wide coding, methylation or gene expression related to specific anatomic locations in the human colon.

By using scRNAseq and scATACseq (Single-cell Assay of Transposase Accessible Chromatin sequencing) we will be able to map open regions in the cell's DNA and RNA, thus providing us with a unique "map" of the cells in the colon as well is their gene expression. ScATACseq visualizes open regions in the chromatin, generating "peaks" which can then be used to map DNA motifs, such as transcription factor binding sites. With the emergence of scATACseq, chromatin accessibility is in combination with gene expression data an extremely useful resource to study cell type specific regulatory DNA interactions. To further study the immunological aspects of the colon, we will extract immune cells from the colon. Lastly, full blood will be extracted to better analyze metabolic risk factors in relation to the colon's metabolic cellular regulation.

The overall purpose of this study is to describe the cellular composition of the human colon and its gene expression using scRNAseq and scATACseq methods. This will potentially provide is with a detailed map of the colon aiding our understanding of how diseases of the colon develop as well as the colons influence on systemic diseases such as type II diabetes.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients referred for out-patient colonoscopy as a result of positive hemoccult.
  • Patients able to read and understand danish.
  • Patients able to give informed consent.
  • Patients of Scandinavian ethnicity.

Exclusion criteria

  • Previous large bowel resections
  • Suspicion pre or intraoperatively of benign or malignant disease of the colon
  • Known inflammatory bowel disease.
  • Immuno-modulation treatment
  • Chemotherapy.
  • Daily smoking
  • > 21 weekly units of alcohol
  • < 18 years of age

Treatment and study plan

Biopsy

Diagnostic Test

Participants included in the study, will have additional biopsies performed during their colonoscopy

Primary outcomes

  1. Profiling of open chromatin regions

    Time frame: 2 years

    Mapping of cell types, including rare cell types, using profiling of open chromatin regions. (ATAC-seq) in mucosal biopsies from the large bowel

  2. Evaluation of metabolic profile

    Time frame: 2 years

    Using bioimpedance, insulin and glucose measurements and CHiP-seq we will determine patient phenotype and epigenetics to evaluate their metabolic risk-profile and correlate this to cell types in the large bowel

Secondary outcomes

  1. Colonic biofilm

    Time frame: 2 years

    By sequencing bacterial DNA in our samples, we will evaluate the mucosa-associated microbiome of the large bowel. This will be correlated to the two primary outcome measures

Sponsors and collaborators

Lead sponsor

Bispebjerg Hospital

Other

Collaborators

  • The Novo Nordisk Foundation Center for Basic Metabolic Research

Registry information

Official study title

Cellular Composition of the Human Colon Using Single-cell RNA and Single-cell ATAC-sequencing.

Acronym: COLATA

Important dates

Study start
2022
Primary completion
2022
Study completion
2024
First posted
Jan 19, 2022
Registry last updated
Jun 12, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.